For personal use only
|
|
- Francine Tate
- 6 years ago
- Views:
Transcription
1 Company Announcement 31 May 2011 Phosphagenics Limited JUNE 2011 NEWSLETTER Attached for release to the market is a copy of the Company s June 2011 Newsletter to shareholders. In addition to receiving the printed Newsletter members and investors can view the Newsletter on the Company s website as noted below. ENDS Enquiries: Dr Esra Ogru Rudi Michelson Chief Executive Officer Monsoon Communications Phosphagenics Limited About Phosphagenics Phosphagenics is commercialising drug delivery applications based on its novel transdermal (drugs administered via skin) TPM Targeted Penetration Matrix technology. TPM is a patient friendly and cost effective system used to deliver proven pharmaceutical and nutraceutical products. The lead product advancing through clinical trials is an oxycodone matrix system for the relief of chronic pain. Phosphagenics shares are listed on the Australian Securities Exchange (POH) and its ADR Level 1 program in the US is with The Bank of New York Mellon (PPGNY). Page 1 of 1
2 PHOSPHAGENICS Newsletter June 2011 PHOSPHAGENICS LIMITED ABN: Dear Shareholders, TPM/oxycodone patch, and two exciting dermatology It is an exciting time to update you again as three diverse Phosphagenics endeavors In our Nutraceutical division, pilot studies in dairy gather momentum towards commercial cattle have shown the benefit of using TPM technology reality. Our ELIXIA product line is expanding to deliver nutritional supplements to cattle, potentially and making a splash in the media through promotions on TVSN, Today Tonight and A Current Affair. Our farmers most significant problems improving the new e-commerce website is open for business and the ELIXIA projects have passed critical milestones. providing a natural product to meet one of dairy quality of milk supply. BodyShaper Cellulite Contour Crème has hit the shelves. We are thrilled with all the emerging opportunities for In the Pharmaceutical division, we continue to work with Phosphagenics. We thank you for your continued support and 3M who are adding expertise to our own, to the benefit of the we look forward to updating you regularly throughout IN THE PIPELINE Product Target Application Research and development Pre-clinical Phase 1 Phase 2 Phase 3 Drug Delivery Pharmaceutical Insulin Insulin Novartis Veterinary Oxycodone CSL Actives Lidocaine Diclofenac Diabetes Diabetes Drug Delivery Dermatology Retinoic Acid US Dermatology Company Global Dermatology Company Acne Dermatitis/Psoriasis Acne Product Target Application Product development Cosmetic ELIXIA ELIXIA high Performance Range ELIXIA AOP9604 Le Métier de Beauté Peau Vierge Active Delivery Oral Natural Anti-ageing Anti-ageing Body Sculpting Anti-ageing IND Granted Market development Commercial production Launch For personal use only Message from Dr Esra Ogru, Joint CEO, Phosphagenics Limited Nutritional Supplements Animal Feed Nutritional Supplements Dairy Cattle Antioxidants Antioxidants KEY Phosphagenics Project Collaborative Project for Commercial Partner
3 PHOSPHAGENICS Personal Care Division PERSONAL CARE UPDATE Phosphagenics Personal Care division has been working towards our goals for 2011, and there has been plenty of activity surrounding the new ELIXIA skincare launch, as well as our new BodyShaper Cellulite Contour Crème. Recent media activity surrounding our new ELIXIA BodyShaper Cellulite Crème has increased the spotlight on Phosphagenics and created exciting opportunities for the brand in Australia and in key export markets. Updated marketplace activity for ELIXIA in recent times include: RETAIL LAUNCHES TVSN mid-march 2011 ELIXIA skincare world launch. Sales expectations exceeded in three days on air (six live on air hours) TVSN mid-may 2011 featured ELIXIA BodyShaper Cellulite Crème. Dr Esra Ogru again in the spotlight launching ELIXIA BodyShaper Cellulite Crème to the Australian market ELIXIA launch into Myer department stores Discussions to sign new ELIXIA distributor in Hong Kong, with exclusive distribution to spa, salon and beauty school channels in Hong Kong and Macau Discussions regarding ELIXIA distribution in India ADVERTISING/MEDIA Today Tonight feature on Channel 7 (11 April 2011) BodyShaper Cellulite Contour Crème More than enquiries at launch (12 April 2011) A Current Affair feature on Channel 9 (17 May 2011) focus on elixia, TPM and Myer Melbourne launch Body + Soul national print ad (10 April 2011) ELIXIA High Performance skincare launch, exclusive to TVSN Body + Soul national print ad (17 April 2011) free HC reader offer x 50 readers Body + Soul national print ad (1 May 2011) elixia High Performance skincare Available online at Woman s Day (30 May 2011 issue) full page featuring ELIXIA BodyShaper, available online and at selected Myer stores The Australian Women s Weekly (June 2011 issue) full page featuring ELIXIA BodyShaper, available online ONLINE ACTIVITY Launched new e-commerce website (18 April 2011) Database members greater than 12,000 Website visits 17,099 (27 April 2011) Unique (new user) visits 12,088 (73% of total visits) Launched ELIXIA Facebook page (18 April 2011) SHAREHOLDERS ASX Press Release (AOD) BodyShaper eight week results and Myer launch (17 May 2011) ASX Press Release (AOD) BodyShaper four week clinical trial results (11 April 2011) Phosphagenics Shareholder VIP Card (Feb April 2011) Offer of 25% discount when purchasing online at using VIP Shareholder code Phosphagenics Newsletter June 2011
4 Phosphagenics recently announced an ongoing collaboration with a major global dermatology company Pharmaceutical Division r & d update TPM enhances dermatology actives Phosphagenics is continuing to make significant inroads into the field of prescription dermatology, with two independent collaborative programs passing critical milestones. COMMERCIAL TPM/OXYCODONE PATCH MANUFACTURE in PARTNERSHIP WITH 3M The TPM/oxycodone patch remains the focus for Phosphagenics Pharmaceutical division, with the commercial development of the patch by 3M the next major milestone. In February, a senior 3M scientist from the Drug Delivery Systems division spent time at Phosphagenics in Melbourne, overseeing the transfer of the technology to the 3M manufacturing facility in Minnesota USA. This process is now complete and 3M are now adapting the Phosphagenics patch to their manufacturing lines to produce a product with superior efficacy, finish and reproducibility compared to the lab scale patches made at Phosphagenics. 3M s brief involvement thus far has already produced a five-fold improvement in patch delivery, dramatically improving the commercial acceptability of the patch, with further improvements expected before development is complete. The next phase of Phosphagenics clinical development for the TPM/oxycodone patch will involve Phase 2/3 human trials in an appropriate pain model. The optimal finished product manufactured by 3M will be used for these critical Phase 2/3 studies. Phosphagenics aims to commence its Phase 2/3 clinical study during the second half of Phosphagenics remains on track to be the world first to develop an effective and reliable patch system for the administration of oxycodone to pain sufferers in a safe and patient-friendly manner. In the first of these alliances, a US-based dermatology company approached Phosphagenics to determine whether TPM could increase the delivery of a potent topical steroid used for the treatment of a range of skin conditions, including eczema, dermatitis and psoriasis. A collaborative program was initiated, whereby TPM was found to significantly increase the delivery of the active into skin in vitro. The results were of sufficient magnitude to compel the US-based dermatology company to apply to the Food and Drug Administration (FDA) for an Investigational New Drug (IND) application, with the aim of conducting a human clinical trial to test the product in the US. As part of the IND submission, a detailed package was assembled documenting all aspects of the TPM technology, its safety and stability. The FDA granted the IND at the beginning of the year, marking the first time that the TPM technology has passed FDA scrutiny. The US-based dermatology company is currently planning the human study which is expected to begin mid-year. TPM/oxycodone Relief Patch Peel-off tab adhesive patch treatment area In relation to the second program, Phosphagenics recently announced an ongoing collaboration with a major global dermatology company to develop a novel anti-acne therapy using the TPM delivery system. Phosphagenics has undertaken extensive formulation development studies for the new product that combines Phosphagenics TPM platform delivery technology with a proprietary anti-acne drug. These formulations have been optimised to maximise drug delivery into the skin and are now in formal stability trials. Although the details of this collaboration must remain confidential, it is of high priority to Phosphagenics, with the potential for immediate access to a global market in partnership with a major player in the field of dermatology. Phosphagenics Newsletter June 2011
5 nutraceutical ELIXIA CHRISTMAS Division 2010 Animal Nutrition Phosphagenics has been actively seeking opportunities to improve human nutrition in recent years and now has an opportunity to apply this same expertise to animal nutrition. Optimal nutrition in animals is crucial for the prevention and management of a range of diseases and conditions. TPM delivery technology is being utilised to enhance the benefits of key vitamins and trace elements in a range of animals, including applications in production animals through to domesticated animals and pets. Dairy INDUSTRY Phosphagenics has partnered with dairy research company Mastitis Management Australia (MMA) to employ its TPM delivery technology to deliver an all-natural formula targeting the improvement in milk quality and therefore increased prices and production capacity. Recent trials of the natural formula have shown the somatic cell counts (SCC) in some cows has been reduced by up to 90% in four weeks. SCC levels are used as a measure of milk quality. The new technology will be sold as a dietary supplement aimed at improving the bioavailability of key nutrients (such as antioxidants), targeting susceptible cattle and providing a benefit as part of a natural holistic approach to control SCC within the herd. Key vitamins and minerals are integral components of the defence of tissues and cells, and influence a cow s resistance to infection. An improved resistance to infection may significantly lower the frequency and shorten the duration of illness, and potentially improve milk quality by reducing somatic cell counts. By employing the versatile TPM delivery technology, we aim to provide a superior benefit to farmers globally by reducing the down time, i.e. withholding periods for the milk produced by the animals treated with expensive drug treatments. mastitis management-australia.com elixia products available AT MYER, online and via TVSN Phosphagenics Limited 11 Duerdin Street, Clayton VIC 3168 Australia PO Box 1415, Clayton South MDC VIC 3169 Ph: Fax: Security Codes: ASX (POH) ; OTCQX (PPGNY) info@phosphagenics.com
Commercialising a platform delivery system: TPM ASX Conference Investor Presentation Dr Esra Ogru Chief Executive Officer
Commercialising a platform delivery system: TPM ASX Conference Investor Presentation Dr Esra Ogru Chief Executive Officer Disclaimer This presentation contains forward-looking statements based on current
More informationHuman Health: Animal Health & Nutrition: Production & Personal Care: In this issue
Welcome to the third instalment of the new Phosphagenics newsletter - the first for 2016. Since our last newsletter issued in October 2015, there has been a considerable amount of news flow and activity.
More informationFor personal use only
I have highlighted on multiple occasions that my business strategy for Phosphagenics is to: Welcome to the fourth instalment of the Phosphagenics shareholder newsletter. Our last shareholder update was
More informationnews Dear Shareholders
PHOSPHAGENICS news LIMITED Dear Shareholders At the end of December 2013 the Company held $8.8 million in cash and cash equivalents. With the federal R&D tax rebates and the continuing recovery of misappropriated
More informationPhosphagenics: Investor Presentation
April 2018 Phosphagenics: Investor Presentation www.phosphagenics.com (ASX : POH) Safe Harbour Statement This presentation, and any representations made before, during or after the presentation, may include
More informationCalzada Ltd. ASX:CZD Investor Overview September 2011
Calzada Ltd ASX:CZD Investor Overview September 2011 Disclaimer This presentation is provided for general information purposes only. It is not intended to be relied upon as advice and does not take into
More informationFor personal use only
ASX/Media Release 31 October 2017 Botanix Pharmaceuticals 4C Quarterly Cash Flow Report Highlights for the quarter ending 30 September 2017: Completed Phase 1 safety, tolerability and pharmacokinetics
More informationMayne Group Limited. ABN AMRO Global Generic Pharmaceutical Conference. Mr Mark Bisset Vice President Global Business Development
Mayne Group Limited ABN AMRO Global Generic Pharmaceutical Conference Mr Mark Bisset Vice President Global Business Development 9 March 2005 Mumbai, India Forward-Looking Statement Comments will be made
More informationJefferies Animal Health Summit
Jefferies Animal Health Summit March 26, 2015 Robert Joseph PRESIDENT & CHIEF EXECUTIVE OFFICER Cautionary Note Regarding Forward-Looking Statements This presentation contains forward-looking statements
More informationFor personal use only. Annual General Meeting 13 November 2017
Annual General Meeting 13 November 2017 Disclaimer The information in this presentation does not constitute personal investment advice. The presentation is not intended to be comprehensive or provide all
More informationBiotech Daily. Thursday August 13, Daily news on ASX-listed biotechnology companies
Biotech Daily Thursday August 13, 2009 Daily news on ASX-listed biotechnology companies * ASX UP, BIOTECH DOWN: VIRALYTICS UP 15%, SUNSHINE DOWN 25% * PHOSPHAGENICS OPTION ON METABOLIC DRUG TO RUB AWAY
More informationFor personal use only
ANNUAL GENERAL MEETING MINTER ELLISON LEVEL 23, 525 COLLINS ST, MELBOURNE VIC 3000 AT 11.00 AM ON 26 NOVEMBER, 2014 CEO S ADDRESS Thank you Roger. Good morning Ladies and Gentlemen. It is a pleasure to
More informationCOMPANY UPDATE ASX / MEDIA RELEASE. The Manager Company Announcements Office ASX Limited
The Manager Company Announcements Office ASX Limited ASX / MEDIA RELEASE COMPANY UPDATE Adelaide, October 27, 2016: LBT Innovations Limited (ASX: LBT) is pleased to release a company update presentation
More informationMeeting the challenges in animal nutrition
Meeting the challenges in animal nutrition Gilbert Weber Corporate Scientist Animal Nutrition & Health DSM Nutritional Products Capital Markets Days 2012 Safe harbor statement This presentation may contain
More informationOBJ Limited Leaders in magnetic enhanced drug delivery technology, products and solutions
OBJ Limited Leaders in magnetic enhanced drug delivery technology, products and solutions Welcome to the 2014 Annual General Meeting DDisclaimeris This Presentation has been prepared by OBJ Limited (ABN
More informationCellmid Investor Newsletter
Cellmid Investor Newsletter 26 March 2019 Message from the CEO Dear Shareholders, The first few months of 2019 have been transformational for Cellmid in terms of strategic focus, senior management capabilities
More informationTransdermal Pain Management to 2020
Transdermal Pain Management to 2020 Products, Markets, Opportunities and Forecasts Greystone Research associates T r a n s d e r m a l P a i n M a n a g e m e n t t o 2 0 2 0 Industry Hierarchical Chain
More informationSciGen Limited. Annual General Meeting Managing Director s Presentation. 28 February 2005
SciGen Limited Annual General Meeting Managing Director s Presentation 28 February 2005 Mr Mark Compton Chief Executive Officer and Managing Director SciGen Limited Biopharmaceutical company Expert focus
More informationFor personal use only
1047 Elwell Court, Palo Alto CA 94303 USA Tel (US): +1 (650) 390 9000 Tel (AU): 1-800-778-662 Fax: +1 650 390 9007 www.airxpanders.com ASX ANNOUNCEMENT AirXpanders issues Shareholder Newsletter PALO ALTO,
More informationQuarterly Report for the Period Ended 31 March 2018
Quarterly Report for the Period Ended 31 March 2018 Highlights Cash receipts of $617,440 received during the March quarter. Main royalty contributors were the SK-II Power Booster (throughout Asia) and
More informationPain Therapeutics, Inc. Pain Therapeutics Announces Update on Drug Portfolio
For More Information Contact: Peter S. Roddy Vice President and Chief Financial Officer Pain Therapeutics, Inc. proddy@paintrials.com 512 501 2450 FOR IMMEDIATE RELEASE Pain Therapeutics Announces Update
More informationMarch Providing innovative solutions to the pharmaceutical, cosmetic, skincare, oral health & consumer products industries
March 2016 Providing innovative solutions to the pharmaceutical, cosmetic, skincare, oral health & consumer products industries This Presentation has been prepared by OBJ Limited (ABN 72 056 482 636) (OBJ
More informationBiotech Daily. Thursday October 2, Daily news on ASX-listed biotechnology companies
Biotech Daily Thursday October 2, 2008 Daily news on ASX-listed biotechnology companies * ASX DOWN, BIOTECHS UP: STARPHARMA UP 15%, CHEMGENEX DOWN 9% * BIOGUIDE: PHOSPHAGENICS VERY DEEP VITAMIN E PIPELINE
More informationASX Announcement MAYNE PHARMA REPORTS STRONGER 1HFY19 RESULTS
22 February 2019 MAYNE PHARMA REPORTS STRONGER 1HFY19 RESULTS Revenues of $274.4m, an increase of 13% on 1HFY18 Reported EBITDA of $65.4m, an increase of 184% on 1HFY18 Underlying EBITDA of $81.2m, an
More informationImaging not only apoptosis. 30 October 2018 AusBiotech Australia Biotech Invest & Partnering 2018 Dr Barbara Meurer Chief Executive Officer
Imaging not only apoptosis. 30 October 2018 AusBiotech Australia Biotech Invest & Partnering 2018 Dr Barbara Meurer Chief Executive Officer 1 The company and a strong IP position Melbourne based biotech
More informationAppendix 4G Corporate Governance Statement
Corporate Governance Statement Melbourne, Australia; 28 August 2017: Starpharma (ASX: SPL, OTCQX: SPHRY) today released its Appendix 4G Key to Disclosures Corporate Governance Council Principles and Recommendations,
More informationCEO BROOKER. Well-established listed Biotech.
BROOKER C o n s u l t i n g CEO Well-established listed Biotech Anatara Lifesciences is an ASX listed company located in Melbourne. With the execution of a major licensing deal with Zoetis, Anatara is
More informationIIS INNOVATIVE INJECTION SYSTEMS NEW PERSPECTIVES, MORE POSSIBILITIES
IIS INNOVATIVE INJECTION SYSTEMS NEW PERSPECTIVES, MORE POSSIBILITIES IIS REVOLUTIONARY ADMINISTRATION TECHNIQUES MORE EFFICIENCY AND SAFETY IIS researches and develops innovative injection systems. Within
More informationHealth Care Logistics: an Enabler of Change BioLogistics in a Changing Healthcare World Northwestern University Transportation Center
Health Care Logistics: an Enabler of Change BioLogistics in a Changing Healthcare World Northwestern University Transportation Center Dave Bode VP, Health Care Solutions DSC Logistics April 20, 2016 Health
More informationDurect Corporation 2003 Annual Report. Delivering biotechnology.
Durect Corporation 2003 Annual Report Delivering biotechnology. We develop controlled-release pharmaceutical delivery systems to relieve chronic pain, target post-operative pain and make drug dosing safer,
More informationA2 Corporation Presentation
A2 Corporation Presentation April 2012 Geoffrey Babidge Managing Director & CEO Disclaimer This presentation has been prepared by A2 Corporation Limited ( A2C ) based on information available to it. No
More informationOrganised by PREVIEW
Organised by PREVIEW WHY COSMOPROF INDIA PREVIEW A NEW SHOW BY BOLOGNA FIERE AND UBM INDIA According to industry experts, the market size of India s beauty, cosmetic and grooming market will touch 20 billion
More informationHealth Care Business Group
Health Care Business Group Joaquin Delgado, Executive Vice President December 17, 2013 2013 3M. All Rights Reserved. 2 3M CONFIDENTIAL 2013 3M. All Rights Reserved. Saving and improving lives around the
More informationFor personal use only
Zelda Therapeutics Ltd ACN 103 782 378 www.zeldatherapeutics.com Level 45 108 St Georges Terrace, Perth Western Australia 6000 DECEMBER 2016 QUARTERLY REPORT Successful $4 million capital raising to fuel
More informationPHARMACEUTICALS EXPORT PROMOTION COUNCIL (Set up by Ministry of Commerce, Govt. of India)
PHARMACEUTICALS EXPORT PROMOTION COUNCIL (Set up by Ministry of Commerce, Govt. of India) COPY Date : 23-02-2010 News / Story reproduced with thanks:- Stockmarkest.com Indian pharmaceutical industry has
More informationFY16 AGM Rob Woolley, Chair Laura McBain, CEO 19 October 2016
FY16 AGM Rob Woolley, Chair Laura McBain, CEO 19 October 2016 SHARE PRICE $ 18 16 14 12 10 8 6 4 2 0 05-Aug-14 30-Aug-14 30-Sep-14 31-Oct-14 30-Nov-14 31-Dec-14 31-Jan-15 28-Feb-15 31-Mar-15 30-Apr-15
More informationSpecial Issue. Mesoblast Limited
Overview is an Australian biotechnology company committed to the commercialization of novel treatments for orthopedic conditions by using its unique adult stem cell technology for the regeneration and
More informationASX Spotlight Conference
ASX Spotlight Conference Duncan Thomson Head of Animal Health Singapore & Hong Kong October 2013 Improving quality of life through innovative cellular therapies Important Notice No offer to sell, issue
More informationASX Spotlight Conference
ASX Spotlight Conference Duncan Thomson Head of Animal Health Singapore & Hong Kong October 2013 Improving quality of life through innovative cellular therapies Important Notice No offer to sell, issue
More informationFor personal use only
Wattle Health Australia Signs HOA with Organic Dairy Farmers of Australia Wattle Health Australia has entered into a non-binding heads of agreement with Organic Dairy Farmers of Australia Pty Ltd, Mason
More informationTo meet the challenge of providing safe, cost-effective medicines for the world s largest
An Executive Summary Biopharma in China: New Initiatives, New Opportunities To meet the challenge of providing safe, cost-effective medicines for the world s largest population, the government of China
More informationWattle Health Australia Limited Enters into Joint Venture with Organic Dairy Farmers of Australia Limited
Enters into Joint Venture with Organic Dairy Farmers of Australia Limited Wattle Health Australia enters into joint venture with Organic Dairy Farmers of Australia ( ODFA ) and Niche Dairy Pty Ltd ( Niche
More informationcompany overview M A R C H
company overview MARCH 2016 our focus INNOVATION in Aesthetics and Dermatology DISCOVERY CLINICAL DEVELOPMENT COMMERCIALIZATION 2 / CONFIDENTIAL and PROPRIETARY the sienna opportunity CLEAR STRATEGY for
More informationFor personal use only
10 April 2013 ASX Announcement ECQ: CYNATA INCORPORATED SIGNS FOUNDATION AGREEMENT The Board of Eco Quest advises that its associate company, Cynata Inc, has signed a Foundation License Agreement (FLA)
More informationLinius Establishes Fundamentals for Global Roll Out
LINIUS TECHNOLOGIES LIMITED (ASX: LNU) LEVEL 18, 101 COLLINS STREET, MELBOURNE VIC 3000 AUSTRALIA t: +61 3 8680 2317 e: info@linius.com Linius Technologies Limited www.linius.com (ASX: LNU) ASX Announcement
More informationTransdermal Drug in Adhesive Delivery Patch
Transdermal Drug in Adhesive Delivery Patch A Technology Outline CC Lee M.Sc.,B.Sc.(Hons) CEO, Director of Technology Transdermal Drug Delivery Offers the Best of IV and Oral Administration IV Oral TDD
More informationKRISANI BIO SCIENCES PVT. LTD.
KRISANI BIO SCIENCES PVT. LTD. Flat B2, 2 nd Floor, Suryateja Apartments, Hindi Nagar, Punjagutta, Hyderabad, Telangana 500078. Email: kkr@krisanibio.com. URL: www.krisanibio.com Contact Number: +91 98494
More informationSpeed your time to market with FDA s expedited programs
Regulatory Sciences Expediting drug approval Speed your time to market with FDA s expedited programs The faster way to marketing submission and drug approval for serious conditions and rare diseases In
More informationSPHERIX ANNOUNCES 2009 FINANCIAL RESULTS
SPHERIX Investor Relations Phone: (301) 897-2564 Email: info@spherix.com SPHERIX ANNOUNCES 2009 FINANCIAL RESULTS BETHESDA, MD, April 1, 2010 - Spherix Incorporated (NASDAQ CM: SPEX), an innovator in biotechnology
More informationDigital Nutraceutical; combining scientifically-validated natural ingredients with digital technology
Digital Nutraceutical; combining scientifically-validated natural ingredients with digital technology Digital technologies have enabled a new era of customer centricity thanks to the data revolution. We
More informationTransdel Pharmaceuticals, Inc. June 2010
Transdel Pharmaceuticals, Inc. June 2010 Safe Harbor Statement The Company cautions you that the statements included in this presentation that are not a description of historical facts are forward-looking
More informationCalzada Ltd ASX:CZD. Presentation to Annual General Meeting 14 November 2012
Calzada Ltd ASX:CZD Presentation to Annual General Meeting 14 November 2012 Disclaimer This presentation is provided for general information purposes only. It is not intended to be relied upon as advice
More informationB&M Forum. Market trends and product positioning
B&M Forum Market trends and product positioning State of the European supplements industry Speaker: Claire Morton, Senior Industry Analyst, Nutrition Business Journal, New Hope Network, US State of the
More informationMayne Pharma Group Limited
Mayne Pharma Group Limited Company Presentation Rodman & Renshaw Annual Investment Conference September 9, 2014 Stefan Cross, President Mayne Pharma USA Mayne Pharma is a diverse global pharma company
More informationGlobal Allied Pharmaceuticals, LLC. Innovation, Research, and Technology. Breaking the bounders, first in its class, thinking outside the box.
Global Allied Pharmaceuticals, LLC. Innovation, Research, and Technology. Breaking the bounders, first in its class, thinking outside the box. The purpose of this presentation Looking for Joint Venture
More informationBiotech Daily. Tuesday May 17, Daily news on ASX-listed biotechnology companies * ASX UP, BIOTECH DOWN: ANTISENSE UP 30%; LBT DOWN 17%
Biotech Daily Tuesday May 17, 2011 Daily news on ASX-listed biotechnology companies * ASX UP, BIOTECH DOWN: ANTISENSE UP 30%; LBT DOWN 17% * MONASH, CSIRO CREATE STEM CELLS FROM KIDNEY CELLS * AVITA PLACEMENT
More informationYour Trusted Source for Market Intel on China s Natural Health Product Industry. USCHPA Presents at World Health Conference
China Updates Your Trusted Source for Market Intel on China s Natural Health Product Industry Special ISSUE 39 April 18, 2013 Ms. Xu asked about China s current dietary supplement industry development
More informationAttention ASX Company Announcements Platform Lodgement of Open Briefing
Attention ASX Company Announcements Platform Lodgement of Open Briefing Advanced Nanotechnology Limited 108 Radium Street Welshpool Western Australia, 6106 Date of lodgement: 4-Oct-2006 Title: Open Briefing.
More informationAssembly Biosciences Jefferies 2015 Microbiome Summit. December 16, 2015
Assembly Biosciences Jefferies 2015 Microbiome Summit December 16, 2015 Forward-Looking Statements This presentation contains forward-looking statements regarding future events. Forward-looking statements
More informationFor personal use only
ASX/Media Release 27 June 2017 12 month operational review highlights significant progress Philadelphia PA and Sydney Australia, 27 June 2017: Medical dermatology company Botanix Pharmaceuticals Limited
More informationInnovative Approaches to Saving Patients Money on Prescription Drug Costs
Innovative Approaches to Saving Patients Money on Prescription Drug Costs April 2018 1 Innovative Approaches to Saving Patients Money on Prescription Drug Costs Executive Summary As prescription drug prices
More informationBUSINESS OBJECTIVES AND FUTURE PLANS
BUSINESS OBJECTIVES AND STRATEGIES Our objectives are to consolidate and strengthen our position to become one of the leading distributors of pharmaceutical products in Zhejiang province. To further develop
More informationPhysiomics Plc. ("Physiomics" or "the Company") Interim Results Statement for the six month period ended 31 December 2015
The Magdalen Centre The Oxford Science Park Robert Robinson Avenue Oxford OX4 4GA UK Tel 01865 784980 Fax 08701 671931 ("Physiomics" or "the Company") Interim Results Statement for the six month period
More informationBusiness Units contract development and manufacturing cost effective processes reliability of supply. total API solution retroviral APIs
Business Units Building on our strong capabilities in chemical development and manufacturing, Laurus Labs has developed an in-house range of APIs and related intermediates. Focusing on chemistries where
More informationAusbiotech Biotech Invest Summit
ASX code: LBT lbtinnovations.com Ausbiotech Biotech Invest Summit 3 December 2014 Lusia Guthrie, CEO Disclaimer This document contains certain forward-looking statements that involve risks and uncertainties.
More informationDRRX. Durect Corporation. Clinical Advancements Six programs in product development
DRRX Durect Corporation 2006 Annual Report Clinical Advancements Six programs in product development Manufacturing Scale-up Preparing for late-stage trials and launch Collaborations/Partnerships Providing
More informationFor personal use only
June 2016 Message from the CEO Dear Shareholders and Investors, Newsletter I am pleased to share this Investor update with shareholders in what has been a period of continued growth in all phases of our
More informationSession 8: Marketing and Strategy (Practitioner) Athena Prib, RTTP Commercial Director, gemaker Chair of Marketing Committee, ATTP
Session 8: Marketing and Strategy (Practitioner) Athena Prib, RTTP Commercial Director, gemaker Chair of Marketing Committee, ATTP Session 8: Marketing and Strategy (Practitioner) Marketing versus selling
More informationConference call transcript for the March 2017 Quarterly Report
ASX ANNOUNCEMENT Conference call transcript for the March 2017 Quarterly Report Sydney Australia, 31 May 2017: Benitec Biopharma Limited (ASX: BLT; NASDAQ: BNTC; NASDAQ: BNTCW) today lodged its transcript
More informationGetting around the North American b2b market successfully Len Monheit, Executive Director, Engredea
Getting around the North American b2b market successfully Len Monheit, Executive Director, Engredea Presentation Outline Current news Market numbers Economics Culture Supply, quality issues (inc. GMP)
More informationHeartbeat of the nation
Presented by: www.romulusbusinessservices.com www.thecbq.ca ONTARIO Heartbeat of the nation Revisiting the factors for Doug Ford s election and understanding the business and economics driving the province
More informationASX Announcement ANNUAL GENERAL MEETING RACV CLUB LEVEL 2, 501 BOURKE ST, MELBOURNE VIC 3000 AT AM ON 29 NOVEMBER, 2018
ANNUAL GENERAL MEETING RACV CLUB LEVEL 2, 501 BOURKE ST, MELBOURNE VIC 3000 AT 10.00 AM ON 29 NOVEMBER, 2018 CEO S ADDRESS Thank you Roger. Good morning Ladies and Gentlemen. It is a pleasure to be speaking
More informationINNOVATION ALMOST 180 MILLION EUROS AREAS OF INNOVATION
From health to beauty INNOVATION IMAGINING FUTURE PRODUCTS 40 Investments in R&D reflect the importance that we attach to the discovery and development of innovative therapeutic and well-being solutions,
More informationFor personal use only
Quarterly Report for the Period Ended 30 June 2017 1. Financial The Company s cash management remains strictly controlled with a balance of approximately $5.366 million at the end of the period. Revenues
More informationPhylogica. Harnessing Biodiversity for Peptide Therapies. Life Sciences Showcase, 23 August 2011 Nick Woolf: CFO & VP Corporate Development
Phylogica Harnessing Biodiversity for Peptide Therapies Life Sciences Showcase, 23 August 2011 Nick Woolf: CFO & VP Corporate Development Introduction Biotech company offering leading peptide drug discovery
More informationTotarol not run of the mill.
Ancient Maori custom demanded that when a totara tree was felled for timber a young seedling had to be planted in its place in order to appease Tane, the god of the forest, for removing one of his 'children
More informationFood and Drug Administration
Food and Drug Administration Drug Regulation BIT 120 FDA Regulatory body that governs testing and marketing of new therapeutic drugs, food, medical devices and procedures Establishes guidelines for how
More informationPATHWAY TO VALUE CREATION NASDAQ: BNTC ASX: BLT
PATHWAY TO VALUE CREATION NASDAQ: BNTC ASX: BLT Annual General Meeting Presentation 8 November 2018 Jerel A. Banks, M.D., Ph.D. Chief Executive Officer and Executive Chairman SAFE HARBOR STATEMENT This
More informationPATHWAY TO VALUE CREATION NASDAQ: BNTC ASX: BLT. For personal use only
PATHWAY TO VALUE CREATION NASDAQ: BNTC ASX: BLT Annual General Meeting Presentation 8 November 2018 Jerel A. Banks, M.D., Ph.D. Chief Executive Officer and Executive Chairman SAFE HARBOR STATEMENT This
More informationNew Dairy Products and Value Chains
Whai Hua Primary Growth Partnership (PGP) Programme New Dairy Products and Value Chains Final Summary Report April 2017 1 Executive Summary Investment. The PGP programme New Dairy Products and Value Chains
More informationCORPORATE GOVERANCE STATEMENT
CORPORATE GOVERANCE STATEMENT The Board of Directors of Kalina Power Limited ( Company ) is responsible for the corporate governance of the Consolidated Entity. The Board guides and monitors the business
More informationCHARTING THE DEVELOPMENT OF A TRUE DIFFERENTIATED PORTFOLIO OF PARENTERAL DELIVERY SYSTEMS
CHARTING THE DEVELOPMENT OF A TRUE DIFFERENTIATED PORTFOLIO OF PARENTERAL DELIVERY SYSTEMS In this article, Alan Shortall, Chief Executive Officer, Unilife Corporation, describes how the company has developed
More informationEli Lilly and Company (LLY) - Financial and Strategic SWOT Analysis Review
Eli Lilly and Company (LLY) - Financial and Strategic SWOT Analysis Review Eli Lilly and Company (LLY) - Financial and Strategic SWOT Analysis Review BioPortfolio has been marketing business and market
More informationTHE USE OF BOVINE SOMATOTROPIN (BST) IN DAIRY CATTLE
THE USE OF BOVINE SOMATOTROPIN (BST) IN DAIRY CATTLE Jorge Estrada and J. E. Shirley General Information We all have heard about the use of BST in lactating dairy cattle during the last 6 to 8 years, but
More informationOffice for Human Subject Protection. University of Rochester
POLICY 1. Purpose Outline the responsibilities and regulatory requirements when conducting human subject research that involves the use of drugs, agents, biological products, or nutritional products (e.g.,
More informationShareholder Update Frequently Asked Questions
22 nd November 2018 Shareholder Update Frequently Asked Questions Dear Shareholders Since last week s announcement we have received a number of questions about the results of the Company s Phase 2 VF00102
More informationFor personal use only
ASX/Media Release 5 February 2018 Company update Philadelphia PA and Sydney Australia, 5 February 2018: Medical dermatology company Botanix Pharmaceuticals Limited (ASX: BOT, Botanix or the Company ) is
More informationFor personal use only
Xped signs JV agreement for China expansion Highlights XPED SIGNS JV AGREEMENT FOR CHINA EXPANSION XPED & COMPLEX SEMICONDUCTOR TO ESTABLISH NEW JV ENTITIES IN CHINA & HONG KONG DR WENJUN SHENG TO BE APPOINTED
More informationXped Limited. Xped signs JV agreement for China expansion XPED SIGNS JV AGREEMENT FOR CHINA EXPANSION
Xped signs JV agreement for China expansion Highlights XPED SIGNS JV AGREEMENT FOR CHINA EXPANSION XPED & COMPLEX SEMICONDUCTOR TO ESTABLISH NEW JV ENTITIES IN CHINA & HONG KONG DR WENJUN SHENG TO BE APPOINTED
More informationTitle: Department: Approved by: Director, Human Research Review and Compliance
Title: Department: Requirements for Investigational New Drug (IND) for Human- Subjects Research Human Research Affairs Policy Type: Partners System-wide Partners System-wide Template Partners HealthCare
More informationCorporate Presentation. June 2015
Corporate Presentation June 2015 Forward Looking Statement/Safe Harbor This presentation and the accompanying oral commentary contain forward-looking statements that involve risks, uncertainties and assumptions.
More informationStrategic Partnership
Strategic Partnership William J. Gole What is the issue? While strategic partnerships have grown in popularity in recent years, they often do not meet their intended objectives. Why is it important? Without
More informationLicense Agreement of Tildrakizumab for Psoriasis in Europe
License Agreement of Tildrakizumab for Psoriasis in Europe July 28 th 2016 Disclaimer This document has been prepared by Almirall, S.A. (the Company ) exclusively for use during the presentation. This
More informationThorney Technologies Ltd ABN
ABN 66 096 782 188 13 September 2017 Dear fellow TEK shareholder I am happy to report that since I last wrote to you in June 2017, TEK has continued to perform strongly and there have been some significant
More informationStatus of Food and Drug Administration Programs and Activities During the Current Government Shutdown
Status of Food and Drug Administration Programs and Activities During the Current Government Shutdown Agency-Wide FDA can perform activities necessary to address imminent threats to the safety of human
More informationFarm Manager (Dry Stock)
(Dry Stock) Background and business focus Established in 1976, Parininihi Ki Waitotara Incorporation (PKW) manages and administers land and land related assets returned to Taranaki Māori following the
More informationOur Story. An Australian-owned-and-operated largest Health Solution E-commerce Store
Our Story An Australian-owned-and-operated largest Health Solution E-commerce Store OUR STORY Breakable is an Australian owned and operated e-commerce store, providing an end to end fast goods solutions
More informationthe 5th Mid-term Business Plan September 14, 2016 Ci:z Holdings Co., Ltd.
the 5th Mid-term Business Plan September 14, 2016 Ci:z Holdings Co., Ltd. Index 1. Background of Formulation of the 5th Mid-term Business Plan 2. Basic Plan 3. Three-year Plan 4. Directions of Individual
More informationGlobal leader in predictive diagnostics ASX: PIQ
Corporate Review Sydney Canary Capital 6 th June 2017 Global leader in predictive diagnostics ASX: PIQ 1 Business model Three synergistic business areas Unifying Promarker platform technology - leverage
More informationToxicology - Problem Drill 24: Toxicology Studies in Pharmaceutical Development
Toxicology - Problem Drill 24: Toxicology Studies in Pharmaceutical Development No. 1 of 10 1. regulates all the drugs products manufactured and sold in the USA. (A) EMEA (B) IND (C) FDA (D) NDA (E) OSHA
More information